Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in rural Senegal.
Increased Plasmodium falciparum resistance to chloroquine has prompted national malaria programs to develop new policies in several African countries. Less than a year after the introduction of amodiaquine/sulfadoxine-pyrimethamine (AQ/SP) as first-line treatment in Senegal, we examined adherence rates to therapy and its efficacy among children. The study was conducted in five dispensaries in rural Senegal. Children aged 2-10 years with a presumptive diagnosis of malaria were prescribed AQ/SP. Thick blood film analyses were carried out on days 0, 3, 7, 14 and 28. Blood and urine samples were collected on day 3 for drug level measurements. The principal caregivers were questioned on treatment adherence. Among the 289 recruited children, 144 had a parasitemia >2500/microl. The results demonstrated markedly good efficacy for the treatment, as no detectable parasitemia was observed on day 28 for 97.9% of the children. However, we noticed that 35.3% of children did not comply with the recommended doses and 62.3% did not exactly adhere to the drug schedule. Despite the good efficacy of the drugs, adherence to the therapeutic scheme was poor. Strategies to promote patient adherence would improve drug performance and thus might help to prevent the rapid emergence of drug resistance.
Souares
Aurélia
A
Institut de Recherche pour le Développement, UR10, Faculté de pharmacie, 4 av de l'Observatoire, 75006 Paris, France. souares@uni-heidelberg.de
Lalou
Richard
R
Sene
Ibra
I
Sow
Diarietou
D
Le Hesran
Jean-Yves
JY
D000655:Amodiaquine / Q000008:administration & dosage* / Q000191:economics; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage* / Q000191:economics; D001294:Attitude to Health / Q000208:ethnology; D017028:Caregivers / Q000193:education; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D010349:Patient Compliance / Q000208:ethnology; D010963:Plasmodium falciparum / Q000187:drug effects; D011739:Pyrimethamine / Q000008:administration & dosage* / Q000191:economics; D012423:Rural Health / Q000592:standards; D012675:Senegal / Q000453:epidemiology; D013413:Sulfadoxine / Q000008:administration & dosage* / Q000191:economics; D016896:Treatment Outcome; D016903:Drug Monitoring
D000962:Antimalarials; D004338:Drug Combinations; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine